



Immunization Case Studies:

A Day at the Clinic

Susan Reeser RN,BSN

Nurse Consultant







Overview

- Review examples of client presentations for vaccine administration
- Determine what vaccines are needed
- At the end of the session identify 3 resources for determining vaccine administration action
- Credit to Donna Weaver, CDC

Story

- A day at the clinic
- Imagine yourself in a role in the story
- Make a memory
- This is a story about
 - sharing solutions
 - actions you can take to increase your knowledge, skills, and abilities in providing vaccines

The day begins...

- Start of a new day at the clinic
- Smell of coffee brewing
- New staff member to be oriented to administer vaccines
- Review the clinic schedule for today



Skills Checklist for Immunization

The Skills Checklist is a self-assessment tool for health care staff who administer immunizations. To complete it, review the competency areas below and the clinical skills, techniques, and procedures outlined for each of them. Score yourself in the Self-Assessment column. If you check **Need to Improve**, you indicate further study, practice, or change is needed. When you check **Meets or Exceeds**, you indicate you believe you are performing at the expected level of competence, or higher.

Supervisors: Use the Skills Checklist to clarify responsibilities and expectations for staff who administer vaccines. When you use it for performance reviews, give staff the op-

portunity to score themselves in advance. Next, observe their performance as they provide immunizations to several patients and score in the **Supervisor Review** columns. If improvement is needed, meet with them to develop a **Plan of Action** (p. 2) that will help them achieve the level of competence you expect; circle desired actions or write in others.

The DVD "Immunization Techniques: Best Practices with Infants, Children, and Adults" ensures that staff administer vaccines correctly. Order online at www.immunize.org/dvd

	es. when you use it for performance reviews, give starr the op-	Self-Assessment		Supervisor Review		
Competency	Clinical Skills, Techniques, and Procedures	Need to Improve	Meets or Exceeds	Need to Improve	Meets or Exceeds	Plan of Action*
A. Patient/Parent Education	Welcomes patient/family, establishes rapport, and answers any questions.					
	2. Explains what vaccines will be given and which type(s) of injection will be done.					
	Accommodates language or literacy barriers and special needs of patient/parents to help make them feel comfortable and informed about the procedure.					
	 Verifies patient/parents received the Vaccine Information Statements for indicated vaccines and had time to read them and ask questions. 					
	5. Screens for contraindications. (MA: score NA-not applicable-if this is MD function.)					
	Reviews comfort measures and after care instructions with patient/parents, inviting questions.					
B. Medical Protocols	I. Identifies the location of the medical protocols (i.e. immunization protocol, emergency protocol, reference material).					
	Identifies the location of the epinephrine, its administration technique, and clinical situations where its use would be indicated.					
	Maintains up-to-date CPR certification.					
	 Understands the need to report any needlestick injury and to maintain a sharps injury log. 					
C. Vaccine Handling	Checks vial expiration date. Double-checks vial label and contents prior to drawing up.					
	Maintains aseptic technique throughout.					
	Selects the correct needle size for IM and SC.					
	Shakes vaccine vial and/or reconstitutes and mixes using the diluent supplied. Inverts vial and draws up correct dose of vaccine. Rechecks vial label.					
	5. Labels each filled syringe or uses labeled tray to keep them identified.					
	 Demonstrates knowledge of proper vaccine handling, e.g. protects MMR from light, logs refrigerator temperature. 					

Competency	Clinical Skills, Techniques, and Procedures	Need to Improve	Meets or Exceeds	Need to Improve	Meets or Exceeds	Plan of Action*
D. Administering	Rechecks the physician's order or instructions against prepared syringes.					
Immunizations	Washes hands and if office policy puts on disposable gloves.	Improve Exceeds Inprove Exceeds Improve Exceeds Improv				
	Demonstrates knowledge of the appropriate route for each vaccine.					
	Positions patient and/or restrains the child with parent's help; locates anatomic landmarks specific for IM or SC					
	 Preps the site with an alcohol wipe using a circular motion from the center to a 2" to 3" circle. Allows alcohol to dry. 					
	 Controls the limb with the non-dominant hand; holds the needle an inch from the skin and inserts it quickly at the appropriate angle (45° for SC or 90° for IM). 					
	7. Injects vaccine using steady pressure; withdraws needle at angle of insertion.					
	8. Applies gentle pressure to injection site for several seconds with a dry cotton ball.					
	Properly disposes of needle and syringe in sharps container. Properly disposes of live vaccine vial.					
	10. Encourages comfort measures before, during and after the procedure.					
E. Records Procedures	Fully documents each immunization in patient's chart: date, lot number, manufacturer, site, VIS date, name/initials.					
	If applicable, demonstrates ability to use IZ registry or computer to call up patient record, assess what is due today, and update computer immunization history.					
	 Asks for and updates patient's record of immunizations and reminds them to bring it to each visit. 					
	b. Review office protocols. c. Review manuals, textbooks, wall charts or other guides. dother staff with patients. g. Practice injections. h. Read Vaccine Information Statements.	I. Review packa I. Be mentored	age inserts. e. I by someone v	Review vaccine who has these	e handling guide skills. j. Role pl	lines or video. f. Observe ay with other staff interac-
	Employee Signature	Date		Plan of Action	Deadline	

Date

Supervisor Signature

Self-Assessment

Supervisor Review

Date of Next Performance Review

All Patients we see today will receive:

- Vaccine Information Statements (VIS)
- Screening questionnaire
 - Contraindications and Precautions
- Comfort measure information



Children



Ellie, Case #1, age 9 weeks

Immunization History

Birth dose Hep B

Here today for 2 month visit

- Screening questionnaire-no concerns
- What vaccines does she need today?
- Where would you look for guidance?




Figure 3. Vaccines that might be indicated for children and adolescents aged 18 years or younger based on medical indications


					fection						
			Immunocompromised	(cell <15% of		Kidney failure, end-		CSF leaks/	Asplenia and persistent	Chronic	
VACCINE ▼	INDICATION ►	Pregnancy	status (excluding HIV infection)	total CD4 cell count	total CD4 cell count	stage renal disease, on hemodialysis	Heart disease, chronic lung disease	cochlear implants	complement component deficiencies	liver disease	Diabetes
Hepatitis B ¹				,							
Rotavirus ²			SCID*								
Diphtheria, tetanus, & acellular (DTaP)	pertussis ³				:						
Haemophilus influenzae type b ⁴											
Pneumococcal conjugate ⁵											
Inactivated poliovirus ⁶					:						
Influenza ⁷											
Measles, mumps, rubella ⁸											
Varicella ⁹											
Hepatitis A ¹⁰											
Meningococcal ACWY ¹¹											
Tetanus, diphtheria, & acellular p (Tdap)	oertussis ¹²										
Human papillomavirus ¹³											
Meningococcal B ¹¹											
Pneumococcal polysaccharide ⁵											
Vaccination according to routine schedule recomm	o the mended	an additio	ended for persons with onal risk factor for which ne would be indicated	a	ind additiona	recommended, I doses may be ed on medical footnotes.	No recommendation	Co	entraindicated	Precaution f	or vaccinatio

^{*}Severe Combined Immunodeficiency


After assessing Ellie's IZ status she could receive:

- Hepatitis B
- Rotavirus
- DTaP
- HIB
- PCV13
- IPV

Rotavirus Vaccine Schedules



RV5 (RotaTeq) Oral Administration Administer at ages 2, 4, and 6 months



RV1 (Rotarix) Oral Administration Administer at ages 2 and 4 months

- For infants who have not received RV vaccine by age 2 months, give the first dose at the earliest opportunity but no later than age 14 weeks 6 days*
- Schedule subsequent doses by observing minimum intervals of 4 weeks between the remaining dose(s)
- If first dose is inadvertently administered at age 15 weeks or older, administer remaining doses*
- Do not administer any RV vaccine beyond the age of 8 months 0 days*

Why do ACIP recommendations not always agree with package inserts?

- ACIP statements and FDA package inserts usually are in close agreement
- FDA requires documentation for all data and recommendations made in the insert
- ACIP may use different data based on expert opinion and public health considerations to
 - formulate its recommendations
 - flexibility to its recommendations
- Published recommendations of national advisory groups (such as ACIP or AAP's Committee on Infectious Diseases) should be considered equally as authoritative as those on the package insert

Combination Vaccines

 Combination vaccines may be used when any of the components are indicated and none are contraindicated.

 The minimum interval between doses is the greatest interval between any of the individual antigens.

Pediarix

- Pediarix contains the vaccine components DTaP, IPV, and HepB
- The primary series is 3 doses (0.5 mL) given intramuscularly at 2, 4, and 6 months of age
- Licensed by the Food and Drug Administration
 - for only the first 3 doses of the DTaP series
 - It should not be given to infants younger than 6 weeks of age nor to children 7 years or older

Diphtheria and Tetanus Toxoid- and acellular Pertussis-containing Vaccines

DTaP (Daptacel)

Ages: 6 weeks through 6 years

Use for: Any dose in the series

Route: Intramuscular (IM) injection

DTaP-IPV (Kinrix)

Ages: 4 years through 6 years

Use for: DTaP dose #5

IPV dose #4

Do NOT use for DTaP doses 1

through 4 OR IPV doses 1 through 3

Route: Intramuscular (IM) injection

Read the package insert that accompanies the product to check for the presence of natural rubber or latex.

DTaP (Infanrix)

Ages: 6 weeks through 6 years

Use for: Any dose in the series

Route: Intramuscular (IM) injection

Read the package insert that accompanies the product to check for the presence of natural rubber or latex.

DTaP-IPV-HepB (Pediarix)

Ages: 6 weeks through 6 years

Use for: DTaP and IPV: Doses #1, #2, and/or #3

HepB: Any dose in the series

Do NOT use for HepB birth dose

Route: Intramuscular (IM) injection

Read the package insert that accompanies the product to check for the presence of natural rubber or latex

Hep B Birth Dose followed by Pediarix

- Use Hep B single-antigen for birth dose
- Pediarix administered at 2, 4, and 6 months
- Dose 4 must be given at 24 weeks or later and at least 16 weeks from dose 1
 - there is no minimum interval between dose 4 and the previous dose.

Pentacel

Pentacel is licensed as a 4-dose series in infants and children at ages 2, 4, 6, and 15-18 months

- It should <u>not</u> be used for any dose in the primary series for children
 - age 5 years or older or
 - as the booster dose for children ages 4-6 years
- The DTaP-IPV component is supplied as a sterile liquid, which is used to reconstitute lyophilized (freeze-dried) ActHIB vaccine.
 - The two components of the vaccine should be stored together in the carton to reduce the chance of giving one component of the vaccine without the other
 - The DTaP-IPV component should never be administered alone

Diphtheria and Tetanus Toxoid- and acellular Pertussis-containing Vaccines

DTaP-IPV/Hib (Pentacel)

Ages: 6 weeks through 4 years

Use for: DTaP and IPV: Doses #1, #2,


#3, and/or #4

Hib: Any dose in the series

Route: Intramuscular (IM) injection

Reconstitute Hib powder ONLY with manufacturer-supplied DTaP-IPV liquid diluent

Should be used immediately after reconstitution Do NOT administer DTaP-IPV w/o Hib



Adolescents




Joshua, Case #3, age 16 years


- Immunization history
 - Completed childhood series
 - Tdap at age 11 years

- Screening questionnaire-no concerns
- What vaccines can he receive today?

Figure 1. Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2017. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]).

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bases in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded in gray.





Meningococcal, Men ACYW

Footnote #11

- Catch-up vaccination:
- Administer Menactra or Menveo vaccine at age 13 through 18 years if not previously vaccinated.
- If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 16 through 18 years, with a minimum interval of at least 8 weeks between doses.
- If the first dose is administered at age 16 years or older, a booster dose is not needed.

Men B, Clinical Discretion:

Footnote # 11

Young adults aged 16 through 23 years (preferred age range is 16 through 18 years)

who are **not at increased risk** for meningococcal disease **may be vaccinated** (for short-term protection) with a 2-dose series of either

- Bexsero (0, ≥1 month)
- Trumenba (0, 6 months)
- The two MenB vaccines are **not** interchangeable
- If the second dose of Trumenba is given at an interval of <6 months, a third dose should be given at least 6 months after the first dose
 - the minimum interval between the second and third dose is 4 weeks

Influenza

Footnote #7

- Routine vaccination:
- Administer influenza vaccine annually to all children beginning at age 6 months. For the 2016-17 season, use of live attenuated influenza vaccine (LAIV) is not recommended.
- For persons aged 9 years and older:
- Administer 1 dose.

Samuel, Case #2, age 18 months

- Immunization history
 - Birth dose
 - Hep B
 - 2 months received
 - DTaP-IPV-Hep B (Pediarix)
 - Hib
 - PCV13
 - Rota
- What vaccines does he need today?
- Where will you look for guidance?

Figure 1. Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2017. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]).

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded in gray.




FIGURE 2. Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind—United States, 2017.

The figure below provides	catch-up schedu	les and minimum intervals between doses for	ontns through 18 years who start late or who are more than 1 mo r children whose vaccinations have been delayed. A vaccine series does not need to be re						
doses. Use the section app	ropriate for the c	hild's age. Always use this table in conjunction	n with Figure 1 and the footnotes that follow. ´	statica, regulatess of the time that has elaps	ed between				
			Children age 4 months through 6 years						
Vaccine	Minimum	Minimum Interval Between Doses							
vaccine	Age for Dose 1	Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dos				
Hepatitis B [†]	Birth	4 weeks	8 weeks and at least 16 weeks after first dose. Minimum age for the final dose is 24 weeks.						
Rotavirus ²	6 weeks	4 weeks	4 weeks ²						
Diphtheria, tetanus, and acellular pertussis ³	6 weeks	4 weeks	4 weeks	6 months	6 months ³				
Haemophilus influenzae type b [¢]	6 weeks	4 weeks if first dose was administered before the 1st birthday. 8 weeks (as final dose) if first dose was administered at age 12 through 14 months. No further doses needed if first dose was administered at age 15 months or older.	4 weeks ⁴ if current age is younger than 12 months and first dose was administered at younger than age 7 months, and at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberix) or unknown. 8 weeks and age 12 through 59 months (as final dose) ⁶ • if current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR • if current age is 12 through 59 months and first dose was administered before the 1st birthday, and second dose administered at younger than 15 months; OR • if both doses were PRP-OMP (PedvaxHIB; Comvax) and were administered before the 1st birthday. No further doses needed if previous dose was administered at age 15 months or older.	8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before the 1st birthday.					
Pneumococcal ⁵	6 weeks	4 weeks if first dose administered before the 1st birthday. 8 weeks (as final dose for healthy children) if first dose was administered at the 1st birthday or after. No further doses needed for healthy children if first dose was administered at age 24 months or older.	4 weeks if current age is younger than 12 months and previous dose given at <7 months old. 8 weeks (as final dose for healthy children) if previous dose given between 7-11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was given before age 12 months. No further doses needed for healthy children if previous dose administered at age 24 months or older.	8 weeks (as final dose) This dose only necessary for children aged 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age.					
Inactivated poliovirus ⁶	6 weeks	4 weeks ⁶	4 weeks ⁶	6 months ⁶ (minimum age 4 years for final dose).					
Measles, mumps, rubella ⁸	12 months	4 weeks							
Varicella ⁹	12 months	3 months							
Hepatitis A ¹⁰	12 months	6 months							
Meningococcal ¹¹ (Hib-MenCY ≥6 weeks;	6 weeks	8 weeks ¹¹	See footnote 11	See footnote 11					

MenACWY-D≥9 mos; MenACWY-CRM≥2 mos)

FIGURE 2. Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind—United States, 2017.

The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. Always use this table in conjunction with Figure 1 and the footnotes that follow.

Children age 4 months through 6 years									
Vaccino	Minimum	Minimum Interval Between Doses							
		Dose 1 to Dose 2	Dose 2 to Dose 3	Dose 3 to Dose 4	Dose 4 to Dos				
Hepatitis B ¹	Birth	4 weeks	8 weeks and at least 16 weeks after first dose. Minimum age for the final dose is 24 weeks.						
Rotavirus ²	6 weeks	4 weeks	4 weeks ²						
Diphtheria, tetanus, and acellular pertussis ³	6 weeks	4 weeks	4 weeks	6 months	6 months ³				
Haemophilus influenzae type b*		4 weeks if first dose was administered before the 1 birthday. 8 weeks (as final dose) if first dose was administered at age 12 through 14 months. No further doses needed if first dose was administered at age 15 months or older.	4 weeks ⁴ if current age is younger than 12 months and first dose was administered at younger than age 7 months, and at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberix) or unknown. 8 weeks and age 12 through 59 months (as final dose) ⁶ • if current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR • if current age is 12 through 59 months and first dose was administered before the 1 st birthday, and second dose administered at younger than 15 months; OR • if both doses were PRP-OMP (PedvaxHIB; Comvax) and were administered before the 1 st birthday. No further doses needed	8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before the 1* birthday.					
Pneumococcai	6 weeks	4 weeks if first dose administered before the 1st birthday. 8 weeks (as final dose for beaking children) if first dose was administered at the 1st birthday or after. No further doses needed for healthy children if first dose was administered at age 24 months or older.	if previous dose was administered at age 15 months or older. 4 weeks if current age is younger than 12 months and previous dose given at <7 months old. 8 weeks (as final dose for healthy children) if previous dose given between 7-11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was given before age 12 months. No further doses needed for healthy children if previous dose administered at age 24 months or older.	8 weeks (as final dose) This dose only necessary for children aged 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age.					
Inactivated poliovirus ⁶	6 weeks	4 weeks ⁶	4 weeks ⁶	6 months ⁶ (minimum age 4 years for final dose).					
Measles, mumps, rubella ⁸	12 months	4 weeks							
Varicella ⁹	12 months	3 months							
Hepatitis A ¹⁰	12 months	6 months							
Meningococcal ^{††} (Hib-MenCY ≥6 weeks; MenACWY-D ≥9 mos; MenACWY-CRM ≥2 mos)	6 weeks	8 weeks ¹¹	See footnote 11	See footnote 11					

After assessing Samuel's IZ status he could receive:

- Hep B
- DTaP
- HIB
- PCV13
- IPV
- Influenza
- MMR
- Varicella
- Hep A

Discussion

- Give VIS for all recommended vaccines
- Recommend all
- MMR and Varicella vs MMRV
- Is the child going to day care
- Other

Samuel

- Hep A
 - initiate series at 12-24 months
- MMRV

Children may also get these vaccines as 2 separate shots: MMR (measles, mumps and rubella) and varicella vaccines.

1 Shot (MMRV) or 2 Shots (MMR & Varicella)?

- · Both options give the same protection.
- One less shot with MMRV.
- Children who got the first dose as MMRV have had more fevers and fever-related seizures (about 1 in 1,250) than children who got the first dose as separate shots of MMR and varicella vaccines on the same day (about 1 in 2,500).

Your doctor can give you more information, including the Vaccine Information Statements for MMR and Varicella vaccines

CDC Immunization Schedules

For Health Care Professionals

BIRTH-18 YEARS & "CATCH-UP" IMMUNIZATION SCHEDULES

Catch-Up Guidance Job Aids

CDC has developed job aids to assist healthcare providers in interpreting figure 2 in the Childhood/Adolescent immunization catch-up schedule.

- Pneumococcal Conjugate Vaccine (PCV) Catch-Up Guidance for Children 4 Months through 18 Years of Age 💈 [3 pages]
- Haemophilus Influenzae type b-Containing Vaccines Catch-Up Guidance for Children 4 Months through 18 Years of Age
 - Hib Vaccine Products: ActHIB, Pentacel, MenHibRix, or Unknown [7] [3 pages]
- Diphtheria, Tetanus, and Pertussis-Containing Vaccines Catch-Up Guidance for Children 4 Months through 18 Years of Age 🔁 [4 pages]

IF current age is	AND#of previous Doses of DTaP or DT	AND	AND	THEN	Next Dose Due
	Unknown or 0)	→	Give Dose 1 (DTaP) today	Give Dose 2 (DTaP) at least 4 weeks after Dose 1
	4	It has been at least 4 weeks since Dose 1	→	Give Dose 2 (DTaP) today	Give Dose 3 (DTaP) at least 4 weeks after Dose 2
4 months through	1	It has not been at least 4 weeks since Dose 1	→	No dose today	Give Dose 2 (DTaP) at least 4 weeks after Dose 1
11 months	2	It has been at least 4 weeks since Dose 2	→	Give Dose 3 (DTaP) today	Give Dose 4 (DTaP) at least 6 calendar months after Dose 3 and at least 15 months of age
	_	It has not been at least 4 weeks since Dose 2	→	No dose today	Give Dose 3 (DTaP) at least 4 weeks after Dose 2
	Unknown or 0)	,	Give Dose 1 (DTaP) today	Give Dose 2 (DTaP) at least 4 weeks after Dose 1
•		It has been at least 4 weeks since Dose 1	→	Give Dose 2 (DTaP) today	Give Dose 3 (DTaP) at least 4 weeks after Dose 2
		It has not been 4 weeks since Dose 1	→	No dose today	Give Dose 2 (DTaP) at least 4 weeks after Dose 1
	2	It has been at least 4 weeks since Dose 2	→	Give Dose 3 (DTaP) today	Give Dose 4 (DTaP) at least 6 calendar months after Dose 3
1 through 3 years	2	It has not been 4 weeks since Dose 2	→	No dose today	Give Dose 3 (DTaP) at least 4 weeks after Dose 2
		It has been at least		If 12 through14 months of age, no dose today	Give Dose 4 (DTaP) at 15 through 18 months of age
	3	6 calendar months since Dose 3	→	If 15 months of age or older, give Dose 4 (DTaP) today	Give Dose 5 (DTaP) at least 6 months after Dose 4 and at 4 through 6 years of age
		It has not been 6 calendar months since Dose 3	→	No dose today	Give Dose 4 (DTaP) at least 6 months after Dose 3

Haemophilus Influenzae type b-Containing Vaccines Catch-Up Guidance for Children 4 Months through 18 Years of Age 2015

Hib Vaccine Products: ActHIB, Pentacel, MenHibRix, or Unknown

IF current age is	AND # of previous doses is	AND	AND	AND	THEN	NEXT DOSE DUE
	Unknown or 0))	→	Give Dose 1 today (Final Dose)	No additional doses needed
		Dose 1 was given before 12 months of age)	→	Give Dose 2 today (Final Dose)	No additional doses needed
		Dose 1 was given at	It has been at least 8 weeks since Dose 1	→	Give Dose 2 today (Final Dose)	No additional doses needed
	1	12 through 14 months of age	It has not been 8 weeks since Dose 1)	No dose today	Give Dose 2 (Final Dose) at least 8 weeks after Dose 1
		Dose 1 was given at 15 months of age or older	→	→	No dose today	No additional doses needed
	2	Dose 1 was given before 12 months of age	Dose 2 was given before 15 months of age	It has been at least 8 weeks since Dose 2	Give Dose 3 today (Final Dose)	No additional doses needed
15 through 59 Months				It has not been 8 weeks since Dose 2	No dose today	Give Dose 3 (Final Dose) at least 8 weeks after Dose 2
			Dose 2 was given at 15 months of age or older	→	No dose today	No additional doses needed
		Dose 1 was given at 12 months of age or older)	→	No dose today	No additional doses needed
		Dose 2 was given before	All doses were given before 12 months of age	→	Give Dose 4 today (Final Dose)	No additional doses needed

Haemophilus Influenzae type b-Containing Vaccines Catch-Up Guidance for Children 4 Months through 18 Years of Age 2015

Hib Vaccine Products: Pedvax and Comvax Vaccines Only

IF current age is	AND # of previous doses is	AND	AND	AND	THEN	NEXT DOSE DUE
	0	→))	Give Dose 1 today (Final Dose)	No additional doses needed
		Dose 1 was given before 12 months of age	→	→	Give Dose 2 today (Final Dose)	No additional doses needed
		Dose 1 was given at	It has been at least 8 weeks since Dose 1)	Give Dose 2 today (Final Dose)	No additional doses needed
	2	12 through 14 months of age	It has not been 8 weeks since Dose 1	→	No dose today	Give Dose 2 at least 8 weeks after Dose 1 (Final Dose)
15 through 59 Months		Dose 1 was given at 15 months of age or older	→	→	No dose today	No additional doses needed
			Dose 2 was given before	It has been at least 8 weeks since Dose 2	Give Dose 3 today (Final Dose)	No additional doses needed
		Dose 1 was given before 12 months of age	15 months of age	It has not been 8 weeks since Dose 2	No dose today	Give dose 3 at least 8 weeks after Dose 2 (Final Dose)
			Dose 2 was given at 15 months of age or older			No additional doses needed
		Dose 1 was given at 12 months or older))	No dose today	No additional doses needed

Pneumococcal Conjugate Vaccine (PCV) Catch-Up Guidance for Children 4 Months through 18 Years of Age 2015

IF current age is	AND # of previous doses is	AND	AND	THEN	NEXT DOSE DUE
	0))	Give Dose 1 today	Give Dose 2 at least 8 weeks after Dose 1 (Final Dose)
		Dose 1 was given before	It has been at least 4 weeks since Dose 1	Give Dose 2 today	Give Dose 3 at least 8 weeks after Dose 2 (Final Dos e)
	1	12 months of age	It has not been 4 weeks since Dose 1	No dose today	Gove Dose 2 at least 4 weeks after Dose 1
	'	Dose 1 was given at	It has been at least 8 weeks since Dose 1	Give Dose 2 today (Final Dose)	No additional doses needed
		12 months of age or older	It has not been 8 weeks since Dose 1	No dose today	Give Dose 2 at least 8 weeks after dose 1 (Final Dos e)
	2	Both doses were given before 12 months of age At least one dose was given at 12 months or older	It has been at least 8 weeks since Dose 2	Give Dose 3 today (Final dose)	No additional doses needed
12-23 months			It has not been 8 weeks since Dose 2	No dose today	Give Dose 3 at least 8 weeks after Dose 2 (Final Dos e)
			It has been at least 8 weeks since Dose 2	Give Dose 3 today (Final Dose)	No additional doses needed
			It has not been 8 weeks since Dose 2	No dose today	Give Dose 3 at least 8 weeks after Dose 2 (Final Dos e)
		All doses were given	It has been at least 8 weeks since Dose 3	Give Dose 4 today (Final Dose)	No additional doses needed
	3	before 12 months of age	It has not been 8 weeks since Dose 3	No dose today	Gove Dose 4 at least 8 weeks after Dose 3 (Final Dos e)
		1 or more doses was given at 12 months of age or older	→	No dose today	No additional doses needed

Bear on a Bike







Adults



Figures 1 and 2 should be read with the footnotes that contain important general information and considerations for special populations.

Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2017

Vaccine	19–21 years	22–26 years	27–59 years	60–64 years	≥ 65 years					
nfluenza¹	1 dose annually									
Td/Tdap²		Substitute Td	ap for Td once, then Td booste	er every 10 yrs						
MMR³		1 or 2 doses	depending on indication							
VAR⁴			2 doses							
HZV⁵				1 d	lose					
HPV-Female ⁶	3 d	oses								
HPV–Male ⁶	3 d	oses								
PCV13 ⁷				1 c	lose					
PPSV23 ⁷		1 oı	2 doses depending on indica	tion	1 dose					
НерА ⁸		20	or 3 doses depending on vacci	ine						
НерВ ⁹			3 doses							
MenACWY or MPSV410		1 or n	nore doses depending on indi	cation						
MenB¹º		2 or 3 doses depending on vaccine								
Hib ¹¹	1 or 3 doses depending on indication									

Figure 2. Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications, United States, 2017

		Immuno- compromised (excluding HIV	CD4+ (cells/µ	fection count LL) ^{3-7,9-11}	Asplenia, persistent complement	Kidney failure, end-stage renal disease, on	Heart or lung disease, chronic	Chronic liver		Healthcare	Men who have sex
Vaccine	Pregnancy ^{1-6,9}	infection) ^{3-7,11}	< 200	≥ 200	deficiencies 7,10,11	hemodialysis ^{7,9}	alcoholism ⁷	disease ⁷⁻⁹	Diabetes ^{7,9}	personnel ^{3,4,9}	with men ^{6,8}
Influenza ¹						1 dose anni	ually				
Td/Tdap²	1 dose Tdap each pregnancy				Substitute Tda	p for Td once, the	n Td booster ev	ery 10 yrs			
MMR ³	cont	raindicated			1 or	2 doses dependi	ng on indicatio	on			
VAR ⁴	cont	raindicated				2 do	oses				
HZV ⁵	cont	contraindicated				1 do	ose				
HPV-Female ⁶		3 doses through age 26 yrs									
HPV-Male ⁶		3 doses through age 26 yrs			3 doses through age 21 yrs						3 doses through ago 26 yrs
PCV13 ⁷						1 d	lose				Part 9
PPSV23 ⁷							1, 2, or 3 d	oses dependir	ng on indicati	on	
HepA ⁸							2 or 3 d	oses dependir	ng on vaccine		
НерВ ⁹		3 doses									
MenACWY or MPSV410		1 or more doses depending on indication									
MenB¹º					2 or 3 doses	depending on va	accine				
Hib ¹¹		3 doses post-HSCT 1 dose recipients only									

Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended for adults with additional medical conditions or other indications



Contraindicated

No recommendation

Table. Contraindications and precautions for vaccines recommended for adults aged 19 years or older*

The Advisory Committee on Immunization Practices (ACIP) recommendations and package inserts for vaccines provide information on contraindications and precautions related to vaccines. Contraindications are conditions that increase chances of a serious adverse reaction in vaccine recipients and the vaccine should not be administered when a contraindication is present. Precautions should be reviewed for potential risks and benefits for vaccine recipient. For a person with a severe allergy to latex, e.g., anaphylaxis, vaccines supplied in vials or syringes that contain natural rubber latex should not be administered unless the benefit of vaccination clearly outweighs the risk for a potential allergic reaction. For latex allergies other than anaphylaxis, vaccines supplied in vials or syringes that contain dry, natural rubber latex may be administered.

Contraindications and precautions for vaccines routinely recommended for adults

Vaccine	Contraindications	Precautions	
All vaccines routinely recommended for adults	Severe reaction, e.g., anaphylaxis, after a previous dose or to a vaccine component	Moderate or severe acute illness with or without fever	

Additional contraindications and precautions for vaccines routinely recommended for adults

Vaccine	Additional Contraindications	Additional Precautions
IIV ¹		History of Guillain-Barré Syndrome within 6 weeks after previous influenza vaccination Egg allergy other than hives, e.g., angioedema, respiratory distress, lightheadedness, or recurrent emesis; or required epinephrine or another emergency medical intervention (IIV may be administered in an inpatient or outpatient medical setting and under the supervision of a healthcare provider who is able to recognize and manage severe allergic conditions)
RIV ¹		History of Guillain-Barré Syndrome within 6 weeks after previous influenza vaccination
LAIV ¹	LAIV should not be used during 2016–2017 influenza season	LAIV should not be used during 2016–2017 influenza season
Tdap/Td	For pertussis-containing vaccines: encephalopathy, e.g., coma, decreased level of consciousness, or prolonged seizures, not attributable to another identifiable cause within 7 days of administration of a previous dose of a vaccine containing tetanus or diphtheria toxoid or acellular pertussis	 Guillain-Barré Syndrome within 6 weeks after a previous dose of tetanus toxoid-containing vaccine History of Arthus-type hypersensitivity reactions after a previous dose of tetanus or diphtheria toxoid-containing vaccine. Defer vaccination until at least 10 years have elapsed since the last tetanus toxoid-containing vaccine For pertussis-containing vaccine, progressive or unstable neurologic disorder, uncontrolled seizures, or progressive encephalopathy (until a treatment regimen has been established and the condition has stabilized)
MMR ²	Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy ³ , human immunodeficiency virus (HIV) infection with severe immunocompromise Pregnancy	Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product) ⁴ History of thrombocytopenia or thrombocytopenic purpura Need for tuberculin skin testing ⁵
VAR ²	Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy ³ , HIV infection with severe immunocompromise Pregnancy	Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product) Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
HZV²	Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy ³ , HIV infection with severe immunocompromise Pregnancy	Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
HPV vaccine		Pregnancy
PCV13	Severe allergic reaction to any vaccine containing diphtheria toxoid	
100 TO 10		The transfer of the transfer o

- 1. For additional information on use of influenza vaccines among persons with egg allergy, see: CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2016–17 influenza season. MMWR 2016;65(RR-5):1–54. Available at www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm.
- 2. MMR may be administered together with VAR or HZV on the same day. If not administered on the same day, separate live vaccines by at least 28 days.
- 3. Immunosuppressive steroid dose is considered to be daily receipt of 20 mg or more prednisone or equivalent for two or more weeks. Vaccination should be deferred for at least 1 month after discontinuation of immunosuppressive steroid therapy. Providers should consult ACIP recommendations for complete information on the use of specific live vaccines among persons on immune-suppressing medications or with immune suppression because of other reasons.
- 4. Vaccine should be deferred for the appropriate interval if replacement immune globulin products are being administered. See: CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(No. RR-2). Available at www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
- 5. Measles vaccination may temporarily suppress tuberculin reactivity. Measles-containing vaccine may be administered on the same day as tuberculin skin testing, or should be postponed for at least 4 weeks after vaccination.
- * Adapted from: CDC. Table 6. Contraindications and precautions to commonly used vaccines. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR 2011;60(No. RR-2):40–41 and from: Hamborsky J, Kroger A, Wolfe S, eds. Appendix A. Epidemiology and prevention of vaccine preventable diseases. 13th ed. Washington, DC: Public Health Foundation, 2015. Available at www.cdc. gov/vaccines/pubs/pinkbook/index.html.

Acronyms of vaccines recommended for adults

HepA	hepatitis A vaccine	LAIV	live attenuated influenza vaccine	PCV13	13-valent pneumococcal conjugate vaccine
HepA-HepB	hepatitis A and hepatitis B vaccines	MenACWY	serogroups A, C, W, and Y meningococcal conjugate	PPSV23	23-valent pneumococcal polysaccharide vaccine
HepB	hepatitis B vaccine		vaccine	RIV	recombinant influenza vaccine
Hib	Haemophilus influenzae type b conjugate vaccine	MenB	serogroup B meningococcal vaccine	Td	tetanus and diphtheria toxoids
HPV vaccine	human papillomavirus vaccine	MMR	measles, mumps, and rubella vaccine	Tdap	tetanus toxoid, reduced diphtheria toxoid, and
HZV	herpes zoster vaccine	MPSV4	serogroups A, C, W, and Y meningococcal		acellular pertussis vaccine
IIV	inactivated influenza vaccine		polysaccharide vaccine	VAR	varicella vaccine
					53/6/20

Heather, Case #4, age 25 years

- Immunization history
 - Childhood immunization series complete, but not varicella
 - No vaccines in the last year
- Screening questionnaire-
 - yes to question #9, she is pregnant

Clicker

- What vaccines can Heather receive today?
 - a) Influenza
 - b) Tdap
 - c) Varicella
 - d) MMR

Figure 2. Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications, United States, 2017

Vaccine	Pregnancy ¹⁻⁶	Immuno- compromised (excluding HIV infection) ^{3-7,11}	HIV infection CD4+ count (cells/µL) ^{3-7,9-11} < 200 ≥ 200	Asplenia, persistent complement deficiencies ^{7,10,11}	Kidney failure, end-stage renal disease, on hemodialysis ^{7,9}	Heart or lung disease, chronic alcoholism ⁷	Chronic liver	Diabetes ^{7,9}	Healthcare personnel ^{3,4,9}	Men who have sex with men ^{6,8,9}
Influenza¹					1 dose annu	ually				
Td/Tdap²	1 dose Tdap each pregnancy			Substitute Tda	p for Td once, the	n Td booster ev	ery 10 yrs			
MMR ³	coi	ntraindicated		1 or	2 doses dependi	ng on indicatio	on			
VAR⁴	coı	ntraindicated			2 do	oses				
HZV⁵	cor	ntraindicated	aindicated 1 dose							
HPV–Female ⁶					3 doses throug	ıh age 26 yrs				
HPV-Male ⁶		3 doses throu	gh age 26 yrs	3 doses through age 21 yrs					3 doses through age 26 yrs	
PCV13 ⁷					1 d	ose				
PPSV23 ⁷						1, 2, or 3 d	oses dependir	ng on indicati	on	
HepA ⁸					v.	2 or 3 de	oses dependir	ng on vaccine		
НерВ ⁹						3 d	oses			
MenACWY or MPSV4	110		1 or more doses depending on indication							
		2 or 3 doses depending on vaccine								
MenB ¹⁰				2 or 3 doses	depending on va	accine				

Recommended for adults who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection

Recommended for adults with additional medical conditions or other indications



Contraindicated

No recommendation

Heather

Influenza

 Pregnant women and women who might become pregnant in the upcoming influenza season should receive IIV.

Tdap

 Pregnant women should receive 1 dose of Tdap during each pregnancy, preferably during the early part of gestational weeks 27-36, regardless of prior history of receiving Tdap.

Heather

- Varicella
 - Currently contraindicated
- MMR
 - Currently contraindicated
 - ACIP recommends that vaccinated women of childbearing age who have received 1 or 2 doses of rubella-containing vaccine and have a rubella serum IgG level that is not clearly positive, should received 1 additional dose of MMR vaccine (maximum of 3 doses). Repeat testing is not recommended.

http://www.immunize.org/askexperts/experts_mmr.a
sp

Maternal Vaccination



Resources for healthcare professionals

Vaccines help keep your pregnant patients and their growing families healthy.

Last Updated September, 2016

Vaccine	Before pregnancy	During pregnancy	After pregnancy	Type of vaccine
Influenza	Yes	Yes, during flu season	Yes	Inactivated
Tdap	May be recommended; it is better to vaccinate during pregnancy when possible	Yes, during each pregnancy	Yes, immediately postpartum, if Tda p never received in lifetime; it is better to vaccinate during pregnancy	Toxoid/ Inactivated
Td	May be recommended	May be recommended, but Tdap is preferred	May be recommended	To∞oid
Hepatitis A	May be recommended	May be recommended	May be recommended	Inactivated
Hepatitis B	May be recommended	May be recommended	May be recommended	Inactivated
Meningococcal	May be recommended	Base decision on risk vs. benefit; inadequate data for specific recommendation	May be recommended	Inactivated
Pneumococcal	May be recommended	Base decision on risk vs. benefit; inadequate data for specific recommendation	May be recommended	Inactivated
HPV	May be recommended (through 26 years of age)	No	May be recommended (through 26 years of age)	Inactivated
MMR	May be recommended; once received, avoid conception for 4 weeks	No	May be recommended	Live
Varicella	May be recommended; once received, avoid conception for 4 weeks	No	May be recommended	Live

Robert, Case #5, age 65 years

- Immunization history
 - Tdap
 - PPSV23
- Screening questionnaire:
 - DOB 2/20/1952
- Do I Need Any Vaccinations Today?
 - Spleen removed 5 years ago car accident
- History of military service



Which Vaccines Do I Need Today?

Vaccines are an important part of helping you stay healthy. Which of these recommended vaccines do you need? Check the boxes that apply to you, and then talk this over with your healthcare provider.

Influenza ("flu") vaccine
I have not had my flu vaccine yet this season (early fall through late spring).
Pneumococcal ("pneumonia") vaccines [Prevnar 13 [PCV13] and Pneumovax 23 [PPSV23])
I am age 65 or older and:
 I have never received any pneumonia vaccine (or I don't remember if I have).
☐ I have received only 1 pneumonia vaccine since I turned 65.
I received 1 or 2 doses of pneumonia vaccine before I turned 65, and it's now been more than 5 years since I received my last dose.
I am younger than age 65 and:
□ I have never received any pneumonia vaccine AND at least one of the following applies to me: I smoke cigarettes and I am age 19 years or older.
 I have a chronic disease of the heart, lung (including asthma, if I am age 19 years or older), liver, or kidneys, or I have sickle cell disease.
I have diabetes or alcoholism.
 I have a weakened immune system due to cancer, Hodgkin's disease, leukemia, lymphoma, multiple myeloma, kidney failure, HIV/AIDS or receiving radiation therapy or taking a medicine that affects my immune system.
I live in a nursing home or other long-term care facility.
☐ I have had an organ or bone marrow transplant.
I have had my spleen removed or have had a cochlear (inner ear) implant or have been told by a healthcare provider that I have leaking spinal fluid.

Figure 2. Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications, United States, 2017

Vaccine	Pregnancy ^{1-6,9}	compromised (excluding HIV	HIV infection CD4+ count (cells/ μ L) ^{3-7,9-11} $< 200 \ge 200$	Asplenia, persistent complement deficiencies ^{7,10,1}	Kidney failure, end-stage renal disease, on chronic hemodialysis ^{7,9} alcoholism ⁷ disease ^{7,9} Diabetes ^{7,9} Healthcare personnel ^{2,4,9} with men ^{6,8,9}				
Influenza¹					1 dose annually				
Td/Tdap²	1 dose Tdap each pregnancy			Substitute Tdap for Td once, then Td booster every 10 yrs					
MMR ³	contraindicated			1 or 2 doses depending on indication					
VAR⁴	contraindicated				2 doses				
HZV⁵	cont	raindicated			1 dose				
HPV-Female ⁶					3 doses through age 26 yrs				
HPV–Male ⁶	3 doses through age 26 yrs			3 doses through age 21 yrs thro					
PCV13 ⁷					1 dose				
PPSV23 ⁷					1, 2, or 3 doses depending on indication				
HepA ⁸				e ,	2 or 3 do <mark>ses dependin</mark> g on vaccine				
НерВ ⁹					3 do <mark>ses</mark>				
MenACWY or MPSV4 ¹⁰				or more doses	depending on indication				
MenB ¹⁰				2 or 3 doses	depending on vaccine				
Hib ¹¹		3 doses post-HSCT recipients only		1/0	lose				
age require	ded for adults w ment, lack docu ı, or lack evidenc	/ho meet the			or adults with additional Contraindicated No recommendations				

Pneumococcal

footnote #7

Special populations

- Adults aged 19 years or older with immunocompromising conditions or anatomical or functional asplenia (described below) should receive
 - PCV13 and a dose of PPSV23 at least 8 weeks after PCV13, followed by a second dose of PPSV23 at least 5 years after the first dose of PPSV23
- But,
 - If the most recent dose of PPSV23 was administered before age 65 years, at age 65 years or older, administer another dose of PPSV23 at least 8 weeks after PCV13 and at least 5 years after the most recent dose of PPSV23

Meningococcal

Footnote # 10

Special populations

- Adults with anatomical or functional asplenia or persistent complement component deficiencies should receive
 - 2-dose primary series of serogroups A, C, W, and Y meningococcal conjugate vaccine (MenACWY) at least 2 months apart and revaccinate every 5 years
 - Serogroup B meningococcal vaccine (MenB) with either a
 - 2-dose series of MenB-4C (Bexsero) at least 1 month apart or
 - 3-dose series of MenB-FHbp (Trumenba) at 0, 1-2, and 6 months.

General Rule*

 All vaccines can be administered at the same visit as all other vaccines.*

*exception:

in persons with functional or anatomic asplenia, pneumococcal conjugate vaccine (PCV13) and <u>Menactra brand</u> meningococcal conjugate vaccines should **not** be administered at the same visit; separate these vaccines by at least 4 weeks

Haemophilus Influenzae type B

Footnote # 11

Special populations

- Adults who have anatomical or functional asplenia or sickle cell disease, or are undergoing elective splenectomy should receive
 - 1 dose of Haemophilus influenzae type b conjugate vaccine (Hib) if they have not previously received Hib.
- Hib should be administered at least 14 days before splenectomy.

Pneumococcal Vaccine Timing-For Adults

DO NOT administer PCV13 and PPSV23 at the same visit.

Age 65 Years or Older

If PCV 13 was given before age 65 years, no add it ional PCV13 is needed.

No history of pneumococcal vaccine PCV 13 Prevnar 13°

1 year (8 weeks for groups 8 & C as defined below) PPSV 23 Pneumovæ®23

Received PPSV23 before age 65 1 уеаг

13

1 year (8 weeks for groups 8 &C as defined below) and 5 years after prior dose of PPSV23 PPSV 23

Received PPSV23 at a ge 65 or older





Age 19-64 Years With Underlying Condition(s)

- Prior dioses count towards doses recommended below and do not need to be repeated.
- If PPSV23 given previously wait one year before giving PCV13
 - for group B, wait at least five years before giving a second dose of PPSV23.
- No more than two doses of PPSV23 recommended before 65th birthday and one dose thereafter.

A. Smoker, or Chronic conditions:

- heart disease (excluding hypertension)
- lung disease (including asthma)
- · liverdisease (including cirrhosis)
- diabetes
- +alcoholism

PPSV 23

B. Immunocompromised (including HIV infection),

> Chronic renal failure, Nephrotic syndrome, or Asplenia (including sickle cell)

PCV 13

8 weeks

PPSV **23**

5 years

23 23

C. CSF leaks or Cochlear implants PCV 13

8 weeks

PPSV 23



Adult Vaccine Administration

Billing issues

• Medicare vs private insurance

Knowledgeable Staff is Key

Before administering vaccines, all personnel who will administer

vaccines should:

- Receive competency-based training
- Have knowledge and skills validated
- Integrate competency-based training into:
 - New staff orientation
 - Annual education requirements
- Ongoing education:
 - Whenever vaccine administration recommendations are updated
 - When new vaccines are added to inventory

		VD "Immunizat is that staff admir	ion Technique nister vaccines	sc Bast Practi	ces with Infan der colline at w	ctions or write in o is, Children, and A www.immunize.org	
			Need to Meets or		Supervisor Review Need to Meets or Plan of Action		
Competency	Clinical Skills, Techniques, and Procedures	Improve	Exceeds	Improve	Exceeds	Pun or Action	
A. Patient/Parent Education	Welcomes patient/family, establishes rapport, and answers any questions.						
Coucasion	Esplains what vaccines will be given and which type(s) of injection will be done.						
	 Accommodates language or literacy barriers and special needs of patient/parents help make them feel comfortable and informed about the procedure. 	ю					
	 Verifies patient/parents received the Vaccine Information Statements for indicates vaccines and had time to read them and solt questions. 						
	5. Screens for contraindications. (MA: score NA-not applicable-if this is MD function	n.)					
	 Reviews confort measures and after care instructions with patient/parents, instring questions. 						
B. Medical Protocols	Identifies the location of the medical protocols (i.e. immunication protocol, emergency protocol, reference material).						
	Identifies the location of the epinephrine, its administration technique, and clinical situations where its use would be indicated.						
	Maintains up-to-date CPR certification.						
	 Understands the need to report any needlestick injury and to maintain a sharps injury log. 						
C. Vaccine Handling	Checks vial expiration date. Double-checks vial label and contents prior to drawing up.						
	Maintains assplic technique throughout.						
	3. Selects the correct needle size for P1 and SC.						
	 Stakes vaccine vial and/or reconstitutes and mises using the cliuent supplied. Inverts vial and draws up correct dose of vaccine. Rechests vial label. 						
	5. Labels each filed syrings or uses labeled tray to leep them identified.						
	Demonstrates knowledge of proper vaccine hardling, e.g. protects MMR from lifegs refrigerator temperature.	he.					

Skills Checklist for Immunization

Skills checklist for immunization http://www.immunize.org/catg.d/p7010.pdf

AND establish an environment that values reporting and investigating errors as part of risk management and quality improvement

Summary

- Vaccine administration can be complex
- Know your
 - Inventory
 - Resources and tools
 - Stay current with vaccine education and updates
- Imagine if...

Resources

Current Immunization Schedules: Children, Adults, Job Aids https://www.cdc.gov/vaccines/schedules/hcp/index.html

Screening Questionnaires

http://www.immunize.org/handouts/screening-vaccines.asp

Skills Checklist for Immunization

http://www.immunize.org/catg.d/p7010.pdf

Maternal Vaccination

https://www.cdc.gov/vaccines/pregnancy/downloads/immunizations-preg-chart.pdf

Vaccine Labels

https://www.cdc.gov/vaccines/hcp/admin/storage/guide/vaccine-storage-labels.pdf

Questions?

Susan Reeser RN, BSN Immunization Nurse Consultant (406) 444-1805 sreeser@mt.gov





"I don't care how 'Nice' she's been, your daughter can't start school until we get her immunization records sent from the North Pole."